Cookies

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this repository, you give consent for essential cookies to be used. You can read more about our Privacy and Cookie Policy.


Durham Research Online
You are in:

A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.

Plummer, R. and Wilson, R. H. and Calvert, H. and Boddy, A. V. and Griffin, M. and Sludden, J. and Tilby, M. J. and Eatock, M. and Pearson, D. G. and Ottley, C. J. and Matsumura, Y. and Kataoka, K. and Nishiya, T. (2011) 'A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.', British journal of cancer., 104 (4). pp. 593-598.

Abstract

Background: On the basis of preclinical studies of NC-6004, a cisplatin-incorporated micellar formulation, we hypothesised that NC-6004 could show lower toxicity than cisplatin and show greater anti-tumour activity in phase I study. Methods: A total of 17 patients were recruited in a range of advanced solid tumour types. NC-6004 was administered intravenously (i.v.) every 3 weeks. The dose escalation started at 10mgm−2 and was increased up to 120mgm−2 according to the accelerated titration method and modified Fibonacci method. Results: One dose-limiting toxicity (DLT) occurred in a patient who was given 90mgm−2 of NC-6004, otherwise any significant cisplatin-related toxicity was not observed or generally mild toxicity was observed. Despite the implementation of post-hydration and pre-medication regimen, renal impairment and hypersensitivity reactions still developed at 120mgm−2, which led to the conclusion that the maximum tolerated dose was 120mgm−2, and the recommended dose was 90mgm−2, although DLT was not defined as per protocol. Stable disease was observed in seven patients. The maximum concentration and area under the concentration–time curve of ultrafilterable platinum at 120mgm−2 NC-6004 were 34-fold smaller and 8.5-fold larger, respectively, than those for cisplatin. Conclusion: The delayed and sustained release of cisplatin after i.v. administration contributes to the low toxicity of NC-6004.

Item Type:Article
Additional Information:Full-text available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049602
Keywords:Cisplatin, DDS, EPR effect, NC-6004, Phase I study, Polymer micelle.
Full text:Full text not available from this repository.
Publisher Web site:http://dx.doi.org/10.1038/bjc.2011.6
Record Created:31 May 2012 16:50
Last Modified:06 Jun 2012 11:21

Social bookmarking: del.icio.usConnoteaBibSonomyCiteULikeFacebookTwitterExport: EndNote, Zotero | BibTex
Usage statisticsLook up in GoogleScholar | Find in a UK Library